XXII Annual Meeting on Gene Therapy

Heidelberg, September 14 -16, 2016

The field of gene therapy continues to progress, with improvements in viral vector profiles, stem cell culturing techniques, and site-specific genome editing platforms. Here, human genome research has recently entered a crucial new phase. Editing of the genome is advancing much faster than considered possible even two years ago. Immunotherapies are being developed for a significant number of patients and diseases. We are quickly moving towards a time when gene therapy may be part of standard cellular therapy for cancer. The future of gene therapy is promising!

At the XXII annual meeting of the German Society for Gene Therapy (DG-GT e.V.) in Heidelberg, translational gene therapy as applied to human disease will be our focus:

  • Trial logistics, preclinical animal model systems and validation studies as well as clinical trial reports which have significant impact for the field
  • basic science studies of mechanisms of gene transfer and control of expression
  • cell-based therapies including all aspects of stem cells and genetically modified cellular approaches
  • novel technological developments for gene transfer, control and silencing, including the CRISPR revolution

There are going to be exciting discussions! See you in Heidelberg!

Download the member letter in English or in German.
Download the participants invitation in Englisch.



President of the German Society for Gene Therapy (DG-GT)

Wolfgang Uckert,
Humboldt University, Max-Delbrück-Center for Molecular Medicine Berlin

Scientific Secretary of the German Society for Gene Therapy (DG-GT)

Hildegard Büning,
Infection Biology & Gene Transfer Institute of Experimental Hematology, Hannover Medical School

 

Meeting President of the German Society for Gene Therapy (DG-GT)

Christof von Kalle, Translational Oncology, National Center for Tumor Diseases (NCT) Heidelberg